Abstract
Although the management of non invasive bladder tumours (NMIBC) has significantly improved the last years, it remains difficult to predict the heterogeneous outcome of such tumours, especially the high grade NMIBC. Obviously, the fluorescence cystoscopy allows the detection of tumours such as carcinoma in situ more efficiently than the white light cystoscopy. In a closed future, we hope that molecular markers will provide an additional tool to improve the personal prognostic of patients and a potential target for treatment.
Collapse